System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

David Tougeron is an expert in Oncology at Centre Hospitalier Universitaire de Poitiers (France). As of October 2026, ScienceLeadR ranks David Tougeron in the top 1% of experts worldwide for Rectal Diseases and Gastrointestinal Neoplasms. David Tougeron has authored 463 publications, the most recent in 2026, and is an investigator in 124 clinical trials, 63 of them ongoing. SLR score: 3,431 (community average: 125). How the SLR is computed.

LeadR Profile

David Tougeron Centre Hospitalier Universitaire de Poitiers France
3 431 ScienceLeadR Reputation 3431

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gastroenterology - Hepatology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Poitiers

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 463

Citations

Citations: 10 637 1st author: 57 Last author: 60 Unique author: 3

Main journals

Ann Oncol 73
J Clin Oncol 62
Dig Liver Dis 40
Eur J Cancer 34
Br J Cancer 13

Best Journals

Ann Oncol 51
J Clin Oncol 40
Lancet Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study.
PMID 42901884 — cells, killer cells, natural, carcinoma, squamous cell, esophageal squamous cell carcinoma, therapeutics		Nat Commun20260
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306).
PMID 42834033 — cells, safety, biological science disciplines, carcinoma, squamous cell, drug therapy, esophageal squamous cell carcinoma, chemotherapy		Nat Commun20260
Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306 ☆.
PMID 42659894 — cells, safety, carcinoma, squamous cell, neoplasms, drug therapy, drug-related side effects and adverse reactions, esophageal squamous cell carcinoma, chemotherapy		ESMO Open20260
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.
PMID 42606323 — cells, neoplasms, sorafenib, bevacizumab, immunotherapy, therapeutics		Clin Cancer Res20260
Interpretable AI to predict anal cancer local failure at 3 years with the FFCD Anabase prospective multicentric cohort.
PMID 42551638 — radiotherapy, anus neoplasms, probability, neoplasms, therapeutics, artificial intelligence		Radiother Oncol20260

Clinical Studies 124

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 17

By phase:

Phase 2 55
Phase 3 35
N/A 20
Phase 2/Phase 3 7
Phase 1/Phase 2 4
Phase 1 2
Phase 3/Phase 4 1

By status:

Recruiting 56
Completed 35
Active not recruiting 16
Not yet recruiting 6
Unknown 6
Terminated 5

By type:

Interventional 114
Observational 10

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 3
multicentric5to9 10
multicentricup10 101

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

63 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Randomized Active Controlled Double blind Multicenter Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First line Treatment of Metastatic Colorectal Cancer (HARMONi GI3)
2025-521587-35-00 — neoplasms, bevacizumab, response evaluation criteria in solid tumors, therapeutics, colorectal neoplasms		Phase 3Recruiting2026
Amivantamab FOLFIRI Versus Cetuximab Bevacizumab FOLFIRI in Participants With Recurrent KRAS NRAS and BRAF Wild type Colorectal Cancer
2024-513853-66-00 — cetuximab, neoplasms, bevacizumab, drug therapy, colorectal neoplasms, chemotherapy		Phase 3Recruiting2025
Amivantamab Chemotherapy Versus Cetuximab Chemotherapy in Treatment na ve Participants with KRAS NRAS and BRAF Wild type Colorectal Cancer
2024-513852-13-00 — cetuximab, neoplasms, drug therapy, therapeutics, colorectal neoplasms, chemotherapy		Phase 3Recruiting2025
ENGIC 06 (PRODIGE 114) FFCD 2401 FRUQUITAS Randomized phase III trial to compare trifluridine tipiracil Fruquintinib versus trifluridine tipiracil alone for metastatic oeso gastric adenocarcinoma
2025-522395-92-00 — trifluridine, adenocarcinoma		Phase 3Recruiting2025
A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gastric or gastroesophageal junction cancers with high levels of a protein called CLDN18 2
2023-508276-11-00 — staphylococcal protein a, esophagogastric junction, neoplasms, adenocarcinoma, multiple chronic conditions, therapeutics, claudins, stomach neoplasms		Phase 3Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS